For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260130:nRSd9983Qa&default-theme=true
RNS Number : 9983Q CVS Group plc 30 January 2026
30 January 2026
CVS Group plc
("CVS" or the "Company")
Total Voting Rights
CVS, the UK's listed veterinary group and a leading provider of veterinary
services, announces that, as of 30 January 2026, the Company's total issued
share capital consists of 70,156,093 ordinary shares of 0.2p each ("Ordinary
Shares") with each one carrying one voting right. The Company holds no
Ordinary Shares in treasury and the total number of voting rights is therefore
70,156,093.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest, or a change to their interest, in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Contacts:
CVS
Group plc
via Camarco
Charlotte Page, Head of Investor Relations
Camarco (Financial
PR)
Ginny Pulbrook
+44 (0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk (http://www.cvsukltd.co.uk/) )
CVS Group is a leading provider of veterinary services with operations in
the UK and Australia and
is listed on the Main Market of the London Stock Exchange. CVS is focused
on providing high-
quality clinical services to its clients and their animals, with outstanding
and dedicated clinical teams
and support colleagues at the core of its strategy.
The Group now operates c.470 veterinary practices across its two
territories, including specialist
referral hospitals and dedicated out-of-hours sites. Alongside the core
Veterinary Practices division,
CVS operates Laboratories (providing diagnostic services to CVS and
third-parties) and an online
retail business ("Animed Direct").
The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TVRAKCBQFBKDPDB
Copyright 2019 Regulatory News Service, all rights reserved